CHICAGO—Several new agents elicited excitement for the treatment of women with advanced breast cancer, including a novel cytotoxic agent that is the first to improve survival as mono therapy in this challenging patient population.
In an international study, patients with metastatic breast cancer refractory to numerous treatments lived 2.5 months longer when treated with eribulin mesylate, a synthetic analog of the novel halichondrin B family, versus single agents alone.
SAN FRANCISCO—Two new studies presented at the 2010 annual meeting of the American Urological Association (AUA) suggest that large-scale prostate cancer screenings can indeed save lives.
Researchers in Innsbruck, Austria, evaluated data from the state of Tyrol within Austria, where an early detection and treatment program has been in place for more than 20 years. They found that these programs have been associated with a reduction in mortality in areas where effective treatment is available to all men.
SAN FRANCISCO—Prostate cancer patients undergoing three-dimensional external beam radiation therapy (3DEBRT) for prostate cancer may be at an increased risk of hip fracture and could benefit from additional measures to improve bone health following treatment, according to a study by Minneapolis researchers. Read More ›
Once-yearly Histrelin Implant Provides Sustained Improvement in Prostate Cancer Patients
BARCELONA—Investigators have documented the long-term efficacy and tolerability of a once-yearly histrelin subdermal implant in men with advanced prostate cancer.
To sign up for our newsletter or print publications, please enter your contact information below.
